D.E. Shaw & Co
OACC

D.E. Shaw & Co’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

D.E. Shaw & Co’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.23M Hold
861,625
– – ﹤0.01% 1884
2026
Q1 		$9.15M Hold
861,625
– – 0.01% 1718
2025
Q4 		$9.16M Hold
861,625
– – 0.01% 1840
2025
Q3 		$9.02M Hold
861,625
– – 0.01% 1765
2025
Q2 		$9.03M Hold
861,625
– – 0.01% 1574
2025
Q1 		$8.79M Buy
+861,625
New +$8.65M 0.01% 1494

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
BGGS
Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

D.E. Shaw & Co's OACC Position: Q2 2026 in Review

D.E. Shaw & Co held its Oaktree Acquisition Corp III Life Sciences (OACC) position steady in Q2 2026 at 861,625 shares worth $9.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1884.

D.E. Shaw & Co first reported a position in OACC in Q1 2025 and has held it in 6 quarters since. 51 funds tracked by Wall St. Rank hold OACC as of Q2 2026.

  • D.E. Shaw & Co held 861,625 shares of Oaktree Acquisition Corp III Life Sciences worth $9.23M as of Q2 2026.
  • D.E. Shaw & Co left its Oaktree Acquisition Corp III Life Sciences share count unchanged in Q2 2026.
  • Oaktree Acquisition Corp III Life Sciences made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1884 holding.
  • D.E. Shaw & Co first reported a position in Oaktree Acquisition Corp III Life Sciences in Q1 2025 and has held it in 6 quarters since.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.